Pancreatic Cancer Research

ResearcherUniversity of Florida HealthActive in the last 2 years

Patrick W. Underwood

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8267-8979; OpenAlex author ID A5011023776. Sources: OpenAlex.

Their work

Papers
28 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 3 papers · 2022: 6 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 28

  1. Localized Pancreatic Cancer among Military Beneficiaries: A National Cancer Database Analysis. First author DOI 10.1093/milmed/usaf465↗
  2. Neoadjuvant Therapy for Localized Pancreatic Cancer. First author DOI 10.3390/cancers18061011↗
  3. Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Co-author DOI 10.3390/cancers18162642↗
  4. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  5. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  6. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable… Co-author DOI 10.1093/bjs/znae085↗
  7. Infiltration of CD3+ and CD8+ lymphocytes in association with inflammation and survival in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0297325↗
  8. A protein-based machine learning approach to the identification of inflammatory subtypes in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2023.06.007↗
  9. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Co-author DOI 10.1158/2767-9764.crc-23-0222↗
  10. Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients. Co-author DOI 10.1371/journal.pone.0281182↗
  11. Changing Practice Patterns and Improving Survival for Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15184464↗
  12. Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. First author DOI 10.1002/cam4.4416↗
  13. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2022.100789↗
  14. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2116764119↗
  15. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Co-author DOI 10.1073/pnas.2200143119↗
  16. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Co-author DOI 10.1158/1535-7163.mct-21-0474↗
  17. Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. First author DOI 10.3389/fonc.2022.806963↗
  18. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
  19. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. First author DOI 10.3389/fonc.2021.688377↗
  20. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Co-author DOI 10.3390/cancers13030440↗
  21. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. First author DOI 10.1002/cam4.3042↗
  22. From tumor microenvironment communicants to biomarker discovery: Selectively packaged extracellular vesicular cargoes in pancreatic cancer. First author DOI 10.1016/j.cytogfr.2020.01.001↗
  23. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  24. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. Co-author DOI 10.1016/j.jddst.2019.101374↗
  25. Nicotine Induces IL-8 Secretion from Pancreatic Cancer Stroma and Worsens Cancer-Induced Cachexia. Co-author DOI 10.3390/cancers12020329↗
  26. The Proteome of Pancreatic Cancer-Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. Co-author DOI 10.1002/pmic.201800394↗
  27. A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies. Co-author DOI 10.21037/atm.2019.03.14↗
  28. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. First author DOI 10.3390/ijms19123836↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jose Gilberto Trevino · 17 shared papers, 2018–2024 · strength 2.43
  2. Steven J. Hughes · 11 shared papers, 2018–2026 · strength 1.88
  3. Jordan M. Cloyd · 4 shared papers, 2024–2026 · strength 1.21
  4. Andrea N. Riner · 7 shared papers, 2020–2024 · strength 1.15
  5. Song Han · 7 shared papers, 2019–2024 · strength 1.05
  6. Kelly M. Herremans · 6 shared papers, 2020–2024 · strength 1.03
  7. Ibrahim Nassour · 4 shared papers, 2023–2026 · strength 0.94
  8. Thomas J. George · 5 shared papers, 2019–2026 · strength 0.92
  9. Timothy Michael Pawlik · 3 shared papers, 2025–2026 · strength 0.76
  10. Daniel R. Principe · 5 shared papers, 2021–2022 · strength 0.72
  11. Hidayatullah G. Munshi · 5 shared papers, 2021–2022 · strength 0.72
  12. Ajay Nmn Rana · 4 shared papers, 2021–2022 · strength 0.59
  13. Michael H. Gerber · 5 shared papers, 2018–2023 · strength 0.59
  14. Abdul Qahar Khan Yasinzai · 2 shared papers, 2026 · strength 0.55
  15. Jordan A. McKean · 2 shared papers, 2026 · strength 0.55
  16. Alessandro Paniccia · 2 shared papers, 2026 · strength 0.55
  17. Gerik W. Tushoski-Alemán · 3 shared papers, 2022–2024 · strength 0.55
  18. Eric David Miller · 2 shared papers, 2025 · strength 0.45
  19. Ashish Manne · 2 shared papers, 2025 · strength 0.45
  20. Mary E. Dillhoff · 2 shared papers, 2025 · strength 0.45
  21. Thao D. Pham · 3 shared papers, 2021–2022 · strength 0.40
  22. Miles E. Cameron · 3 shared papers, 2020–2022 · strength 0.37
  23. Sarah M. Judge · 3 shared papers, 2018–2022 · strength 0.34
  24. Andrew R. Judge · 3 shared papers, 2018–2022 · strength 0.34
  25. Sandeep Kumar · 2 shared papers, 2022 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.